o2h Ventures investment spotlight – revolutionising prostate cancer treatment

Prostate cancer is the most common cancer among men, particularly those over 50, and the numbers in the UK alone highlight the urgent need for better treatments. While current therapies extend survival, there’s still a significant gap in improving patient quality of life and long-term outcomes. That’s where Stratosvir, an innovative biotech company backed by o2h Ventures, is stepping in to make a difference.

A New Approach to Cancer Treatment

Stratosvir is developing next-generation viral immunotherapies designed to overcome the limitations of existing treatments. Unlike earlier approaches that require direct injection into tumors, Stratosvir’s technology enables intravenous delivery, allowing for multiple doses and improved patient accessibility. This breakthrough makes their therapy more effective, scalable, and easier to administer—unlocking new possibilities for cancer treatment beyond prostate cancer.

What Sets Stratosvir Apart?

• Third-generation viruses: Unlike first- and second-generation oncolytic viruses, which are quickly eliminated by the immune system, Stratosvir’s engineered viruses are designed to be more effective, safer, and longer-lasting.
• Targeted & scalable: Their technology enhances precision and affordability, making it a promising alternative to existing immunotherapies.
• Expanding potential: While starting with prostate cancer, Stratosvir’s platform has the potential to treat multiple forms of advanced cancer, significantly broadening its market impact.

Momentum in Biotech & Investment Potential

With investor confidence in oncolytic virus therapies rising—demonstrated by the recent IPO success of CG Oncology—Stratosvir is well-positioned to attract strategic partnerships and drive meaningful progress in cancer treatment. Their unique approach has already shown promising results in early lab testing, with key preclinical milestones on the horizon.

At o2h Ventures, we recognized Stratosvir’s potential early, investing in 2024 through our human health SEIS fund alongside Proven Connect, the translational arm of Prostate Cancer Research. We’ve actively supported their fundraising, leveraged our strategic network, and provided hands-on guidance to help accelerate their journey.

What’s Next?

Stratosvir has already secured platform proof of principle, filed key intellectual property, and received support from two Innovate UK grants. Their next steps focus on preclinical safety and toxicity studies—critical milestones that will bring their groundbreaking therapy closer to clinical application.

With strategic backing from Cancer Research Horizons, Deep Science Ventures, and strong investor interest, Stratosvir is on track to transform prostate cancer treatment and set the stage for broader cancer immunotherapy innovations.